Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) said its new powder formulation of trofinetide, marketed as DAYBUE STIX, is now available in the United States for the treatment of Rett syndrome. The U.S. Food and Drug Administration approved the formulation in December 2025.
DAYBUE STIX is a dye- and preservative-free powder designed to be mixed with water-based liquids before oral administration. Acadia said the powder version is bioequivalent to the original DAYBUE oral solution, which received FDA approval in 2023.
The therapy is approved for adults and pediatric patients aged two years and older who are diagnosed with Rett syndrome, a rare genetic neurological disorder that primarily affects girls and leads to significant cognitive and physical impairments.
“Initial feedback from a small group of caregivers following the limited launch revealed that more than 80% of early users reported satisfaction with DAYBUE STIX,” said Tom Garner, Acadia’s Chief Commercial Officer.
The powder is packaged in single-use packets and can be mixed with a variety of beverages, including juice, tea, lemonade and hydration drinks, allowing caregivers to adjust the taste to better suit patients.
Clinical data supporting DAYBUE STIX is based on results from the Phase 3 LAVENDER study, which evaluated the original oral solution formulation. A separate bioequivalence study confirmed that the powder and liquid versions deliver comparable levels of the medication.
Acadia also provides patient assistance through its Acadia Connect program, which offers financial support resources and prescription guidance for patients and caregivers. The company noted that the original oral solution formulation of DAYBUE will continue to be available.